Bank of America Corp DE Has $772,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Bank of America Corp DE boosted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 9.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,472 shares of the company’s stock after buying an additional 5,983 shares during the quarter. Bank of America Corp DE owned approximately 0.31% of UroGen Pharma worth $772,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC bought a new position in UroGen Pharma in the 4th quarter valued at $1,472,000. Bank of New York Mellon Corp grew its position in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after buying an additional 6,430 shares during the period. Oppenheimer & Co. Inc. bought a new position in shares of UroGen Pharma during the fourth quarter worth $126,000. Rhumbline Advisers grew its stake in UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after acquiring an additional 1,402 shares during the period. Finally, Alliancebernstein L.P. increased its stake in UroGen Pharma by 751.5% during the 4th quarter. Alliancebernstein L.P. now owns 199,259 shares of the company’s stock worth $2,122,000 after purchasing an additional 175,859 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on URGN shares. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 22nd. Scotiabank began coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Thursday, May 8th. The Goldman Sachs Group lowered their price target on shares of UroGen Pharma from $16.00 to $3.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Finally, Oppenheimer reduced their price objective on shares of UroGen Pharma from $36.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.14.

UroGen Pharma Stock Up 43.4%

UroGen Pharma stock opened at $7.37 on Monday. The company has a market capitalization of $339.81 million, a PE ratio of -2.34 and a beta of 0.40. UroGen Pharma Ltd. has a 12-month low of $3.42 and a 12-month high of $20.70. The firm’s fifty day moving average is $8.68 and its 200 day moving average is $10.16. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analysts’ expectations of $22.71 million. As a group, sell-side analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.